Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences ( (TLSA) ) has provided an announcement.
On September 24, 2025, Tiziana Life Sciences announced its participation in the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. The company presented a scientific poster detailing the design of a Phase 2a trial for nasal foralumab, a novel treatment for non-active secondary progressive multiple sclerosis. This presentation highlights Tiziana’s commitment to advancing innovative therapies for MS, potentially impacting their market position by addressing a population with limited treatment options.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed for intranasal delivery, aimed at treating neuroinflammatory and neurodegenerative diseases such as multiple sclerosis. The company emphasizes alternative routes of immunotherapy to improve efficacy, safety, and tolerability compared to traditional methods.
Average Trading Volume: 373,730
Technical Sentiment Signal: Buy
Current Market Cap: $219.6M
Learn more about TLSA stock on TipRanks’ Stock Analysis page.